Research publications

Alfred Health research outcomes are published in a wide range of peer reviewed journals. 

Search or browse research publications by year, research area, publication type or keyword.

Clear filter
Publication Details
Reducing Dietary Symptoms in Irritable Bowel Syndrome and IBD

Gibson PR, Shepherd SJ

(2011), In: Bayless TM and Hanauer SB (eds), Advanced Therapy in Inflammatory Bowel Disease 3rd Edition, Volume 1, People's Medical Publishing House-USA, Shelton, USA, Chapter 40, 249-56

Optimizing Use of Methotrexate

Foley A, Gibson PR

(2011), In: Irving PM, Siegel CA, Rampton DS, Shanahan F (eds), Clinical Dilemmas in Inflammatory Bowel Disease: New Challenges, Second Edition, Wiley-Blackwell, Oxford, UK, Chapter 21, 98-101

A rapid infusion protocol is safe for total dose iron polymaltose: time for change

Garg M, Morrison G, Friedman A, Lau A, Lau D, Gibson PR

(2011), Intern Med J, 41(7), 548-54

Self-administered, inhaled methoxyflurane improves patient comfort during nasoduodenal intubation for computed tomography enteroclysis for suspected small bowel disease: a randomized, double-blind, placebo-controlled trial

Moss A, Parrish FJ, Naidoo P, Upton A, Prime H, Leaney B, Gibson PR

(2011), Clin Radiol, 66(2), 125-31

Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease

Haines ML, Ajlouni Y, Irving PM, Sparrow MP, Rose R, Gearry RB, Gibson PR

(2011), Inflamm Bowel Dis, 17(6), 1301-7

Difficulties and possibilities with thiopurine therapy in inflammatory bowel disease--proceedings of the first Thiopurine Task Force meeting

van Asseldonk DP, Sanderson J, de Boer NK, Sparrow MP, Lémann M, Ansari A, Almer SH, Florin TH, Gearry RB, Mulder CJ, Mantzaris G, van Bodegraven AA; Thiopurine Task Force Interest Group

(2011), Dig Liver Dis, 43(4), 270-6

Optimizing thiopurine therapy in inflammatory bowel disease

Chevaux JB, Peyrin-Biroulet L, Sparrow MP

(2011), Inflamm Bowel Dis, 17(6), 1428-35

Use of thiopurine testing in the management of inflammatory bowel diseases in clinical practice: a worldwide survey of experts

Roblin X, Oussalah A, Chevaux JB, Sparrow M, Peyrin-Biroulet L

(2011), Inflamm Bowel Dis, 17(12), 2480-7

Thiopurine immunomodulators in ulcerative colitis: moving forward with current evidence

La Nauze RJ, Sparrow MP

(2011), Curr Drug Targets, 12(10), 1406-12

Response to Clarke K, Regueiro M. Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission

Friedman AB, Sparrow MP

(2011), Inflamm Bowel Dis, 17(12), E161-2

Endoscopic mucosal resection outcomes and prediction of submucosal cancer from advanced colonic mucosal neoplasia

Moss A, Bourke MJ, Williams SJ, Hourigan LF, Brown G, Tam W, Singh R, Zanati S, Chen RY, Byth K

(2011), Gastroenterology, 140(7), 1909-18

Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection

Zeuzem S, Asselah T, Angus P, Zarski JP, Larrey D, Müllhaupt B, Gane E, Schuchmann M, Lohse A, Pol S, Bronowicki JP, Roberts S, Arasteh K, Zoulim F, Heim M, Stern JO, Kukolj G, Nehmiz G, Haefner C, Boecher WO

(2011), Gastroenterology, 141(6), 2047-55

Pegylated interferon and ribavirin for the treatment of chronic hepatitis C

Kemp W, Roberts S

(2011), Clin Med Insights Ther, 3, 137-50

Telaprevir for retreatment of HCV infection

Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio

(2011), N Engl J Med, 364(25), 2417-28

Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1

Sievert W, Dore GJ, McCaughan GW, Yoshihara M, Crawford DH, Cheng W, Weltman M, Rawlinson W, Rizkalla B, Depamphilis JK, Roberts SK; CHARIOT Study Group

(2011), Hepatology, 53(4), 1109-17

Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B

Patterson SJ, George J, Strasser SI, Lee AU, Sievert W, Nicoll AJ, Desmond PV, Roberts SK, Locarnini S, Bowden S, Angus PW

(2011), Gut, 60(2), 247-54

Effect of low-level HCV viraemia at week 24 on HCV treatment response in genotype 1 patients

Baleriola C, Rawlinson WD, Dore GJ, Chaverot S, Stelzer-Braid S, Yoshihara M, Crawford D, Sievert W, McCaughan G, Weltman M, Cheng W, Rizkalla B, Dubois D, Thommes J, Roberts S

(2011), Antivir Ther, 16(2), 173-80

The prevalence of significant liver fibrosis and cirrhosis in haemophilia patients infected with hepatitis C using FibroScan

Kitson M, Roberts S, Kemp W, Iser D, Walsh M, McCarthy P, Street A, Tran H

(2011), Haemophilia, 17(2), 316-7

Investigation of the safety of irreversible electroporation in humans

Thomson KR, Cheung W, Ellis SJ, Federman D, Kavnoudias H, Loader-Oliver D, Roberts S, Evans P, Ball C, Haydon A

(2011), J Vasc Interv Radiol, 22(5), 611-21

Hepatic TLR2 & TLR4 expression correlates with hepatic inflammation and TNF-α in HCV & HCV/HIV infection

Berzsenyi MD, Roberts SK, Preiss S, Woollard DJ, Beard MR, Skinner NA, Bowden DS, Visvanathan K

(2011), J Viral Hepatitis, 18(2), 852-60

20 21 22 23 24